These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7528958)

  • 1. Pharmacologic management of benign prostatic hyperplasia--changing times.
    Smith AY
    West J Med; 1994 Nov; 161(5):521-3. PubMed ID: 7528958
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacologic treatment of benign prostatic hyperplasia].
    Castro Díaz D
    Actas Urol Esp; 1997 May; 21(5):437-40. PubMed ID: 9412167
    [No Abstract]   [Full Text] [Related]  

  • 3. The place of pharmacologic treatment in benign prostatic hyperplasia.
    Caine M
    Semin Urol; 1985 Nov; 3(4):311-6. PubMed ID: 2441447
    [No Abstract]   [Full Text] [Related]  

  • 4. Benign Prostatic Hyperplasia Implications for Pharmacologic Treatment and Perioperative Care.
    Leedahl DD; Vo PH; Maxson PM; Lovely JK
    J Pharm Pract; 2013 Feb; 26(1):52-8. PubMed ID: 22797835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.
    Nichol MB; Knight TK; Wu J; Barron R; Penson DF
    J Urol; 2009 May; 181(5):2214-21; discussion 2221-2. PubMed ID: 19296986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transurethral enzyme injection--future management of benign prostatic hyperplasia.
    Darson MF; Barrett DM
    Mayo Clin Proc; 1998 Sep; 73(9):908-11. PubMed ID: 9737232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic intervention in benign prostatic hypertrophy. Proceedings of a symposium held in conjunction with the 1988 American Urological Association meeting. Boston, Massachusetts, June 2, 1988.
    Urology; 1988 Dec; 32(6 Suppl):1-31. PubMed ID: 2462298
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacotherapy for benign prostatic hyperplasia.
    Narayan P; Indudhara R
    West J Med; 1994 Nov; 161(5):495-506. PubMed ID: 7528957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of benign prostatic hyperplasia. Alternatives to standard therapy.
    Silverstein JI; Badlani GH; Smith AD
    Clin Geriatr Med; 1990 Feb; 6(1):69-84. PubMed ID: 1689206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.
    Pool JL
    Br J Clin Pract; 1996; 50(3):154-63. PubMed ID: 8733335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the medical management of benign prostatic hyperplasia.
    Jewett MA; Klotz LH;
    CMAJ; 2007 Jun; 176(13):1850-1. PubMed ID: 17576985
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of alpha-blockers in the management of benign prostatic hyperplasia.
    Lowe FC; Stark E
    N Y State J Med; 1993 Mar; 93(3):169-73. PubMed ID: 7681155
    [No Abstract]   [Full Text] [Related]  

  • 13. Facilitating the medical management of benign prostatic hyperplasia in primary care.
    Kirby R; Kirby M; Fitzpatrick J
    BJU Int; 2009 Sep; 104(6):751-3. PubMed ID: 19663880
    [No Abstract]   [Full Text] [Related]  

  • 14. [Medical therapy of benign prostatic hyperplasia].
    Altarac S
    Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of benign prostatic hyperplasia.
    Gray M; Allensworth D
    Urol Nurs; 1997 Dec; 17(4):137-41. PubMed ID: 9451241
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of 4-chloro-7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid on the intraurethral pressure in a rat model of benign prostatic hyperplasia.
    Choi BR; Soni KK; Zhang LT; Lee SW; So I; Kim HK; Park JK
    Int J Urol; 2016 Mar; 23(3):259-65. PubMed ID: 26646436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management and future trends in benign prostatic hyperplasia (BPH).
    Fitzpatrick JM
    Ir Med J; 1997 Nov; 90(7):256, 258. PubMed ID: 10036815
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
    Dedhia RC; Calhoun E; McVary KT
    J Urol; 2008 Jan; 179(1):220-5. PubMed ID: 18001791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.